Published in J Neuroinflammation on September 09, 2013
Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice. Metab Brain Dis (2013) 1.04
Splenectomy reduces infarct volume and neuroinflammation in male but not female mice in experimental stroke. J Neuroimmunol (2014) 0.93
Essential role of program death 1-ligand 1 in regulatory T-cell-afforded protection against blood-brain barrier damage after stroke. Stroke (2014) 0.93
Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother (2015) 0.90
Different immunological mechanisms govern protection from experimental stroke in young and older mice with recombinant TCR ligand therapy. Front Cell Neurosci (2014) 0.88
Antigen-specific immune reactions to ischemic stroke. Front Cell Neurosci (2014) 0.86
Functional role of regulatory lymphocytes in stroke: facts and controversies. Stroke (2015) 0.84
Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke. Front Cell Neurosci (2014) 0.81
Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J Immunol (2014) 0.81
Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders. Front Cell Neurosci (2014) 0.79
Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153. PLoS One (2015) 0.78
Sex differences and the role of PPAR alpha in experimental stroke. Metab Brain Dis (2015) 0.78
Sex differences in the immune response to experimental stroke: Implications for translational research. J Neurosci Res (2017) 0.78
Are Microglial Cells the Regulators of Lymphocyte Responses in the CNS? Front Cell Neurosci (2015) 0.77
PD-1 modulates steady-state and infection-induced IL-10 production in vivo. Eur J Immunol (2013) 0.77
PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation. Stroke (2015) 0.76
Roles of programmed death protein 1/programmed death-ligand 1 in secondary brain injury after intracerebral hemorrhage in rats: selective modulation of microglia polarization to anti-inflammatory phenotype. J Neuroinflammation (2017) 0.75
Differential induction of PD-1/PD-L1 in Neuroimmune cells by drug of abuse. Int J Physiol Pathophysiol Pharmacol (2015) 0.75
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol (2004) 7.16
A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity (2008) 6.73
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med (2006) 5.88
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation (2006) 4.61
Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol (2010) 4.37
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol (1998) 4.14
Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab (2006) 3.91
Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke (2009) 3.55
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol (2003) 3.37
Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol (2006) 3.28
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood (2010) 3.21
PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med (2003) 3.05
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med (2003) 3.00
Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett (2002) 2.80
T- and B-cell-deficient mice with experimental stroke have reduced lesion size and inflammation. J Cereb Blood Flow Metab (2007) 2.75
PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol (2001) 2.71
Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke (2002) 2.50
Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci (2007) 2.47
Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood (2010) 2.17
Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. J Exp Med (2004) 1.89
Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion. J Neuroimmunol (1994) 1.85
Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS) I. Stroke (1999) 1.80
The use of flow cytometry to evaluate temporal changes in inflammatory cells following focal cerebral ischemia in mice. Brain Res (2002) 1.77
Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest (2004) 1.71
Leukocyte infiltration in acute hemispheric ischemic stroke. Stroke (1993) 1.69
The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE. Eur J Immunol (2009) 1.55
Lymphocytic infiltration and expression of intercellular adhesion molecule-1 in photochemically induced ischemia of the rat cortex. J Cereb Blood Flow Metab (1995) 1.50
Progression of ischaemic stroke and excitotoxic aminoacids. Lancet (1997) 1.49
PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur J Immunol (2007) 1.47
CD8+CD122+ regulatory T cells recognize activated T cells via conventional MHC class I-alphabetaTCR interaction and become IL-10-producing active regulatory cells. Int Immunol (2008) 1.27
Estradiol and G1 reduce infarct size and improve immunosuppression after experimental stroke. J Immunol (2010) 1.25
Leukocyte count predicts outcome after ischemic stroke: the Northern Manhattan Stroke Study. J Stroke Cerebrovasc Dis (2007) 1.23
Astrocyte proliferation following stroke in the mouse depends on distance from the infarct. PLoS One (2011) 1.04
Programmed death-1 pathway limits central nervous system inflammation and neurologic deficits in murine experimental stroke. Stroke (2011) 1.03
Intrastriatal B-cell administration limits infarct size after stroke in B-cell deficient mice. Metab Brain Dis (2012) 0.98
Oestrogen-mediated protection of experimental autoimmune encephalomyelitis in the absence of Foxp3+ regulatory T cells implicates compensatory pathways including regulatory B cells. Immunology (2010) 0.95
Costimulation of T cells. Am J Respir Crit Care Med (2000) 0.92
B7-H1 and CD8+ Treg: the enigmatic role of B7-H1 in peripheral tolerance. Eur J Immunol (2009) 0.83
Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab (2006) 3.91
Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol (2006) 3.28
T- and B-cell-deficient mice with experimental stroke have reduced lesion size and inflammation. J Cereb Blood Flow Metab (2007) 2.75
A G-protein-coupled estrogen receptor is involved in hypothalamic control of energy homeostasis. J Neurosci (2006) 2.40
Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res (2005) 2.39
GPR30 contributes to estrogen-induced thymic atrophy. Mol Endocrinol (2007) 1.78
Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol (2004) 1.77
Regulatory B cells limit CNS inflammation and neurologic deficits in murine experimental stroke. J Neurosci (2011) 1.63
Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int Immunol (2007) 1.59
Functional assay for human CD4+CD25+ Treg cells reveals an age-dependent loss of suppressive activity. J Neurosci Res (2003) 1.53
The protective effect of 17beta-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-alpha. Am J Pathol (2003) 1.49
Pain evaluation and response to buprenorphine in rats subjected to sham middle cerebral artery occlusion. Contemp Top Lab Anim Sci (2002) 1.48
Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J Immunol (2009) 1.46
Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res (2006) 1.46
Inhalational anesthetics as neuroprotectants or chemical preconditioning agents in ischemic brain. J Cereb Blood Flow Metab (2006) 1.40
Gender-specific response to isoflurane preconditioning in focal cerebral ischemia. J Cereb Blood Flow Metab (2007) 1.38
Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation. J Immunol (2003) 1.37
Recombinant T cell receptor ligand treats experimental stroke. Stroke (2009) 1.33
CD4+FoxP3+ regulatory T-cells in cerebral ischemic stroke. Metab Brain Dis (2010) 1.33
Identification of Bphs, an autoimmune disease locus, as histamine receptor H1. Science (2002) 1.33
Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol (2009) 1.32
Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice through cytokine switch. J Immunol (2004) 1.30
Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis (2008) 1.29
Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J Neurochem (2006) 1.26
Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL mice and inhibits the recruitment of inflammatory cells into the central nervous system. J Immunol (2003) 1.26
Estradiol and G1 reduce infarct size and improve immunosuppression after experimental stroke. J Immunol (2010) 1.25
Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J Neuroimmunol (2005) 1.24
Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand. J Neurosci (2009) 1.18
Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol (2009) 1.17
Effects of combined estrogen and progesterone on brain infarction in reproductively senescent female rats. J Cereb Blood Flow Metab (2004) 1.16
Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1. Immunology (2009) 1.16
Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injury. J Immunol (2005) 1.11
IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke. Metab Brain Dis (2013) 1.11
Therapy with recombinant T-cell receptor ligand reduces infarct size and infiltrating inflammatory cells in brain after middle cerebral artery occlusion in mice. Metab Brain Dis (2011) 1.09
Estrogen inhibition of EAE involves effects on dendritic cell function. J Neurosci Res (2002) 1.09
Estrogen is renoprotective via a nonreceptor-dependent mechanism after cardiac arrest in vivo. Anesthesiology (2010) 1.08
Evaluation of the effects of 17beta-estradiol (17beta-e2) on gene expression in experimental autoimmune encephalomyelitis using DNA microarray. Endocrinology (2002) 1.07
Characterization of human platelet binding of recombinant T cell receptor ligand. J Neuroinflammation (2010) 1.07
Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis. J Neuroimmunol (2010) 1.05
Down-modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitis. J Neurosci Res (2010) 1.04
RTL therapy for multiple sclerosis: a Phase I clinical study. J Neuroimmunol (2010) 1.04
Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS inflammation in wild-type B-cell-sufficient mice. Metab Brain Dis (2013) 1.04
Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effects. Eur J Immunol (2013) 1.04
Phenotypic changes in immune cell subsets reflect increased infarct volume in male vs. female mice. Transl Stroke Res (2013) 1.03
T lymphocytes do not directly mediate the protective effect of estrogen on experimental autoimmune encephalomyelitis. Am J Pathol (2004) 1.03
Programmed death-1 pathway limits central nervous system inflammation and neurologic deficits in murine experimental stroke. Stroke (2011) 1.03
Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG. J Neuroimmune Pharmacol (2009) 1.03
Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice. Clin Immunol (2007) 1.02
Animal models of ischemic stroke: balancing experimental aims and animal care. Comp Med (2004) 1.01
Estrogen receptor-1 (Esr1) and -2 (Esr2) regulate the severity of clinical experimental allergic encephalomyelitis in male mice. Am J Pathol (2004) 1.01
Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells. J Immunol (2006) 1.01
MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis. J Immunol (2008) 1.00
Inhalational anesthetics as preconditioning agents in ischemic brain. Curr Opin Pharmacol (2007) 1.00
T-cell hybridoma specific for myelin oligodendrocyte glycoprotein-35-55 peptide produced from HLA-DRB1*1501-transgenic mice. J Neurosci Res (2004) 1.00
Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. Eur J Immunol (2011) 1.00